Gilead Sciences (NASDAQ:GILD) Given New $105.00 Price Target at Wells Fargo & Company

Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective lifted by Wells Fargo & Company from $100.00 to $105.00 in a report issued on Thursday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock. A number of other equities research analysts also recently weighed in on the company. Needham […]

Leave a Reply

Your email address will not be published.

Previous post Piper Sandler Issues Pessimistic Forecast for Rapid7 (NASDAQ:RPD) Stock Price
Next post Proteome Sciences (LON:PRM) Reaches New 12-Month Low – Time to Sell?